Asian Myeloproliferative Neoplasm (MPN) Registry

Launched by THE UNIVERSITY OF HONG KONG · May 21, 2023

Keywords

ClinConnect Summary

**Summary of the Asian Myeloproliferative Neoplasm (MPN) Registry Trial**

The Asian Myeloproliferative Neoplasm (MPN) Registry is a research study aimed at understanding various blood disorders known as myeloproliferative neoplasms (MPNs). These conditions, which include Polycythemia Vera, Essential Thrombocythemia, and different stages of Primary Myelofibrosis, involve the bone marrow producing too many blood cells. This study is open to adults aged 18 and older who have been diagnosed with one of these disorders according to specific medical guidelines. Participants will need to provide their consent to join the study.

If you or a family member has been diagnosed with one of these conditions, you may be eligible to participate. The study involves collecting health information from participants to help researchers learn more about these diseases and how they affect patients over time. This could provide valuable insights that may improve future treatments. The trial is currently recruiting participants, and it welcomes individuals of all genders. If you're interested, it’s important to discuss this opportunity with your healthcare provider to see if it’s the right fit for you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Age ≥ 18 years old at the time of diagnosis of MPN.
• 2. Subject was diagnosed with one of the following disorders according to the 2017 WHO classification (for patients diagnosed before 2017, the bone marrow reports will be re-evaluated according to the 2017 WHO classification):
• • 1. Polycythaemia vera
• • 2. Essential thrombocythemia
• • 3. Primary myelofibrosis, pre-fibrotic/early stage
• • 4. Primary myelofibrosis, overt fibrotic stage
• • 5. Post-polycythaemia vera myelofibrosis
• • 6. Post-essential thrombocythaemia myelofibrosis
• • 7. MPN-unclassifiable
• • 3. All subjects need to provide informed consent.
• Exclusion Criteria:
• A subject will not be eligible if he/she meets any of the following criteria:
• • 1. Subject was diagnosed with myelodysplastic syndrome, myelodysplastic syndrome/myeloproliferative neoplasm, or chronic myeloid leukaemia BCR-ABL1 positive, under the 2017 WHO classification